Article
Thiopurine 6TG treatment increases tumor immunogenicity and response to immune checkpoint blockade.
Oncoimmunology - 1 Jan 2023
Nazerai Loulieta, Willis Shona Caroline, Yankilevich Patricio, Di Leo Luca, Bosisio Francesca Maria, Frias Alex, Bertolotto Corine, Nersting Jacob, Thastrup Maria, Buus Soren, Thomsen Allan Randrup, Nielsen Morten, Rohrberg Kristoffer Staal, Schmiegelow Kjeld, De Zio Daniela
Abstract excerpt
Immune-checkpoint inhibitors (ICI) are highly effective in reinvigorating T cells to attack cancer. Nevertheless, a large subset of patients fails to benefit from ICI, partly due to lack of the cancer neoepitopes necessary to trigger an immune response. In this study, we used the thiopurine 6-thioguanine (6TG) to induce random mutations and thus increase the level of neoepitopes presented by tumor cells....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.